Klarquist Sparkman, LLP
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
A panel of human variable heavy (VH) single domain monoclonal antibodies specific for cell-surface glypican-2 (GPC2) are described. Methods for the diagnosis and treatment and GPC2-positive cancer are also described. Recombinant immunotoxins comprised of a GPC2-specific VH domain antibody and a clinically used form of Pseudomonas exotoxin A (PE38) were generated and shown to inhibit GPC2-positive neuroblastoma tumor cell growth and inhibit neuroblastoma xenograft growth in nude mice, without significant toxicity. Chimeric antigen receptors comprising a GPC2-specific VH single domain antibody are also described. T cells expressing the GPC2-specific CARs potently killed GPC2-positive neuroblastoma cells in a dose-dependent manner.
The United States of America, as represented by the Secretary, Department of Health and Human Services
A C A C C C C A C A A C C C C C C
A61K C07K A61P C07K C07K C12N C07K A61K C07K A61K A61K C07K C07K C12N C12N C07K C07K
inventional inventional inventional inventional additional additional additional inventional inventional additional inventional additional additional additional inventional inventional inventional
Nan Dimiter S. Mitchell
Li Dimitrov Ho